Stocks · News reference
Aclarion CEO Says In Letter To Shareholders Company Saw 141% Year-Over-Year Scan Volume Growth In First Half Of 2026; $16.3M Cash, No Debt With Runway Into Second Half Of 2027
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Aclarion Broadens CLARITY Trial Enrollment Criteria to Accelerate Enrollment
Aclarion announced revised inclusion/exclusion criteria for its CLARITY clinical trial to accelerate patient enrollment. The new criteria, approved at 9 of 11 active sites, better reflect real-world chronic low back pain patients while maintaining scientific rigor. The company expects meaningful enrollment acceleration and will provide an updated timeline for initial readout by year-end, though the overall trial duration remains on track.
Aclarion Has Received A Decision To Grant European Patent Number EP3056919 Titled "MR SPECTROSCOPY SYSTEM AND METHOD FOR DIAGNOSING PAINFUL AND NON-PAINFUL INTERVERTEBRAL DISCS"
https://register.epo.org/application?number=EP16152919
Aclarion Announces University Of Arizona College Of Medicine - Phoenix As New Clinical Site In Its CLARITY Trial